High-potency cannabis dominates Germany's booming market

Following Germany's decision to remove medical cannabis from its list of narcotic drugs in April 2024, a thriving commercial market has rapidly emerged. Over a 12-month period, one online dispensary saw its available products grow from 266 to 401 varieties, with nearly 1,000 different cannabis flower products offered throughout the study. The median THC concentration remained relatively stable, but prices dropped significantly—decreasing by approximately 0.003€ per week—suggesting intense market competition as suppliers vie for customers in this newly legalized space.

The study reveals clear patterns in what German consumers are purchasing: products with 20-29.9% THC made up more than two-thirds of total demand, and consumers strongly preferred higher-potency options. For every percentage point increase in THC content, demand rose substantially, while higher prices drove demand down significantly. Notably, about half of all products changed prices at least once during the study period, with price reductions consistently triggering increased sales. This dynamic pricing and aggressive competition suggest that a robust market is developing rapidly.

However, researchers express concern that market trends may not align with public health best practices. The strong consumer preference for cheap, high-THC products contrasts sharply with medical evidence on safe cannabis use, raising questions about whether current German regulations adequately protect patients' health. As the world watches Germany's medical cannabis market evolve, this case study highlights the tension between market forces and evidence-based medicine—a challenge that will likely shape cannabis policy discussions globally.